Oncodesign is Biotechnology in France that focus on translational biomarkers business. Founded in 1995. They cover business area such as Oncodesign SA, research and development work, new therapeutic and diagnostic tool, pharmaceutical firm, biotech company, public research institution, investment group, integrate drug discovery service, vivo pharmacology service, proof, concept stage, pharmacokinetic, drug candidate, translational biomarker, biodecontamination/biosafety, biobanking service.
1995
( 29 years old in 2024 )
Translational Biomarkers
-
20 rue Jean Mazen
B.P. 27627
21076 Dijon
France
Private
Oncodesign SAresearch and development worknew therapeutic and diagnostic toolpharmaceutical firmbiotech companypublic research institutioninvestment groupintegrate drug discovery servicevivo pharmacology serviceproofconcept stagepharmacokineticdrug candidatetranslational biomarkerbiodecontamination/biosafetybiobanking service
* We use standard office opening hours in near Oncodesign's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Oncodesign is Biotechnology business from France that founded in 1995 (29 years old in 2024), Oncodesign business is focusing on Translational Biomarkers.
Oncodesign headquarter office and corporate office address is located in 20 rue Jean Mazen B.P. 27627 21076 Dijon France.
Oncodesign was founded in France.
In 2024, Oncodesign is currently focus on translational biomarkers sector.
Above is snippet of Google Trends for "translational biomarkers" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Oncodesign, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
